Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue , 2011, Pages S75-S83

  Piroth, Lionel ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ALGORITHM; ARTICLE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ALGORITHMS; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS;

MLCS; MLOWN;

EID: 84862726366     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/S2210-7401(11)70012-2     Document Type: Article

References (29)

1. Cacoub, P., Halfon, P., Rosenthal, E., Bailly, F., Sadr, F.B., Benhamou, Y., et al. Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: modifications in three consecutive large surveys between 2004 and 2009. J Hepatol 53 (2010), 230–237.
2. Piroth, L., Martha, B., Minello, A., Grappin, M., Chavanet, P., Treatment of chronic hepatitis C in HIV-infected patients: From clinical trials to field practice. Scand J Infect Dis 40 (2008), 561–564.
3. Lewden, C., May, T., Rosenthal, E., Burty, C., Bonnet, F., Costagliola, D., et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The «Mortalité 2000 and 2005» surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 48 (2008), 590–598.
4. Rosenthal, E., Salmon-Céron, D., Lewden, C., Bouteloup, V., Pialoux, G., Bonnet, F., et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey ANRS EN19). HIV Med 10 (2009), 282–289.
5. Berenguer, J., Alvarez-Pellicer, J., Martín, P.M., López-Aldeguer, J., Von-Wichmann, M.A., Quereda, C., et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 50 (2009), 407–413.
6. Bani-Sadr, F., Lapidus, N., Bedossa, P., De Boever, C.M., Perronne, C., Halfon, P., et al. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis 46 (2008), 768–774.
7. Gadalla, S.M., Preiss, L.R., Eyster, M.E., Goedert, J.J., Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia. J Viral Hepat 18 (2011), 161–169.
8. Sherman, K.E., Shire, N.J., Rouster, S.D., Peters, M.G., James Koziel, M., Chung, R.T., Horn, P.S., Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 128 (2005), 313–327.
9. Ramos, B., Núñez, M., Toro, C., Sheldon, J., García-Samaniego, J., Ríos, P., Soriano, V., Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients. J Infect 54 (2007), 173–179.
10. Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 364 (2011), 2417–2428.
11. Treviño, A., de Mendoza, C., Parra, P., Rodríguez, C., Madejón, A., Plaza, Z., et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antivir Ther 16 (2011), 413–416.
12. Trimoulet, P., Belzunce, C., Faure, M., Wittkop, L., Reigadas, S., Dupon, M., et al., Hepatitis C, virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. HIV Med 12 (2011), 506–509.
13. Chary, A., Winters, M.A., Kottilil, S., Murphy, A.A., Polis, M.A., Holodniy, M., Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV-and HCVcoinfected patients. J Infect Dis 202 (2011), 889–893.
14. Winters, M.A., Chary, A., Eison, R., Asmuth, D., Holodniy, M., Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients. J Med Virol 82 (2010), 791–798.
15. Bruno, S., Shiffman, M.L., Roberts, S.K., Gane, E.J., Messinger, D., Hadziyannis, S.J., Marcellin, P., Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 51 (2010), 388–397.
16. Jacobson, I.M., McHutchison, J.G., Dusheiko, G., Di Bisceglie, A.M., Reddy, K.R., Bzowej, N.H., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364 (2011), 2405–2416.
17. Poordad, F., McCone, J. Jr., Bacon, B.R., Bruno, S., Manns, M.P., Sulkowski, M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364 (2011), 1195–1206.
18. Bacon, B.R., Gordon, S.C., Lawitz, E., Marcellin, P., Vierling, J.M., Zeuzem, S., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364 (2011), 1207–1217.
19. Lange, C.M., Zeuzem, S., IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 55 (2011), 692–701.
20. Chu, T., Kulkarni, R., Gane, E., Roberts, S., Stedman, C., Angus, P., et al. The effect of host IL28B genotype on early viral kinetics during interferon free treatment in patients with chronic hepatitis C. J Hepatol, 54, 2011, S52.
21. Ge, D., Fellay, J., Thompson, A.J., Simon, J.S., Shianna, K.V., Urban, T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461 (2009), 399–401.
22. Rallón, N.I., Soriano, V., Naggie, S., Restrepo, C., Goldstein, D., Vispo, E., et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 25 (2011), 1025–1033.
23. Qurishi, N., Kreuzberg, C., Lüchters, G., Effenberger, W., Kupfer, B., Sauerbruch, T., et al. Effect of antiretroviral therapy on liverrelated mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362 (2003), 1708–1713.
24. Bräu, N., Salvatore, M., Ríos-Bedoya, C.F., Fernández-Carbia, A., Paronetto, F., Rodríguez-Orengo, J.F., et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 44 (2006), 47–55.
25. Macias, J., Berenguer, J., Japon, M.A., Giron, J.A., Rivero, A., Lopez-Cortes, L.F., et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodefi-ciency virus/hepatitis C virus. Hepatology 50 (2009), 1056–1063.
26. Seden, K., Back, D., Khoo, S., New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 65 (2010), 1079–1085.
27. Descamps, D., Chaix, M.L., Montes, B., Pakianather, S., Charpentier, C., Storto, A., et al. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviralnaive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother 65 (2010), 2620–2627.
28. Zeuzem, S., Sulkowski, M., Zoulim, F., Sherman, K., Alberti, A., Wei, L., et al. Long term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the extend study. Hepatology, 52, 2010, 436A.
29. Liu, Q., Zhou, H., Liu, L., Chen, X., Zhu, R., Cao, Z., Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study. BMC Bioinformatics, 12, 2011, 294.